Final IHC Diagnosis Panel
The Final IHC Diagnosis Panel represents a pivotal tool in the realm of cancer diagnosis and personalized medicine. This innovative approach employs a tailored selection of markers and antibodies based on the specific site of biopsy and suspected cancer type, allowing for precise and individualized assessments. Pathologists collaborate closely with clinicians to curate unique combinations of markers, ensuring the most accurate identification and confirmation of the primary tumor site.
This enables the visualization of molecular markers within tissue samples, facilitating the identification of abnormal cell activity. Furthermore, the Final IHC Diagnosis Panel often incorporates predictive biomarker testing, offering insights into the tumor's behavior and response to treatment.
By harnessing the power of molecular profiling and marker-based analysis, this diagnostic panel represents a critical step forward in enhancing cancer diagnosis and tailoring therapeutic strategies to each patient's unique needs.
Disclaimer: In no event shall the liability of TATA 1MG exceed the amount of actual cost of test charges incurred by the customer as stated on the invoice issued by Tata 1mg.
.png){kind=small}
YES 
NO 
